Why the study?
What is the frequency and clinical course of sensorineural hearing loss in neonatal ECMO survivors?
What is the frequency and clinical course of sensorineural hearing loss in neonatal ECMO survivors?
Sensorineural hearing loss is a significant, potentially late-onset and progressive neurologic morbidity in neonatal ECMO survivors, highlighting the need for long-term audiologic monitoring.
Neonatal ECMO survivors merit extended audiologic surveillance for late-onset progressive SNHL; extends prevalence data and supports targeted monitoring protocols.
The follow-up information of sensorineural hearing loss (SNHL) in neonatal extracorporeal membrane oxygenation (ECMO) survivors was reviewed by Medline search (1985-1996) using indexing terms; ECMO, follow-up outcome. Only seven reports (from six different centres) provide information on the results of audiologic assessment in 371 ECMO survivors with follow-up duration of 1-10 years. SNHL is a significant neurologic morbidity in neonatal ECMO survivors with a reported frequency of 3-21% (average 7.5%, 28 of 371). From three of the seven reports that provide information of clinical features in the survivors with SNHL, SNHL is often an isolated disability (16 of 19, 84%) and the loss is usually bilateral involving high frequencies. SNHL can be late-onset (7 of 19, 37% diagnosed after infancy) and progressive. Multicentre prospective studies with regular comprehensive audiologic assessment until bilateral thresholds can be obtained are urgently required to define the course of SNHL. Basic research is needed to evaluate the role of various factors (e.g., peroxynitrite and free radicals) in the pathogenesis of SNHL. The information generated will help to develop preventive measures and cost-effective management of these ECMO survivors.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: